Date: March 3rd 2009


 

Record Registrations for BioTrinity 2009 (April 2-3)

UK's Premier Biotechnology and Investment Conference

Registrations for BioTrinity 2009 have surged in recent weeks, and we're delighted to announce record registration levels are 50% higher than last year.  With four weeks to go, the UK's Premier Biotech and Investment Conference boasts the participation of thirty VCs and investors with over $33bn under management among more than 230 companies confirmed as participating.  60% of the top 20 global pharma now have senior licensing presence confirmed including AstraZeneca, Roche, Novartis, Eli Lilly and GSK.

Five key facts about BioTrinity 2009 - Oxford

 12 of world's top 20 global pharma represented
 230 companies already confirmed from 14 countries
 Partnering is live and uniquely takes place in private rooms
 Gala Dinner at an Oxford College
 30 VCs and Investors already confirmed 

For the first time, BioTrinity 2009 will be opened by Lord Davies of Abersoch CBE, the Minister of State for Trade and Investment at DBERR and the FCO, who will be discussing how the UK government will be fighting the economic challenges facing our industry.

Also for the first time, BioTrinity 2009 will also feature plenaries and panel discussions involving some of Oxford's most successful entrepreneurs Ian Nicholson, Bryan Morton, Anker Lundemose and Bruce Savage, as well as the entrpreneurs John Burt, David Knowles and Ken Powell drawn from across the UK who have returned nearly $500m of value to their investors.  

35 corporate presentations will be made by companies selected from Oxford, London, Cambridge as well as Bristol, Southampton, Kent, Nottingham, Manchester and Newcastle, making BioTrinity a UK Biotechnology Showcase.  The latest addition is Heptares Therapeutics, which just completed a £21m funding round.

In yet another first, BioTrinity 2009 will feature live recording of interviews by PharmaTV adjacent to the main networking hub, so if you want to appear on the groundbreaking online TV channel for the biopharma industry, make sure you are in Oxford from April 2-3, 2009.

BioTrinity unites the UK’s biotech industry, and provides an ideal platform to meet with pharma, investors and biotech companies in the most beautiful city in England, just 1 hours' drive from Heathrow International Airport. The updated programme for BioTrinity has been published online and can be downloaded.

...........................................................................................

Is your company missing from the list of companies attending BioTrinity 2009?

   AstraZeneca

Bristol Myers-Squibb

Eli Lilly

   Genzyme

GSK

Merck

   Novartis

(OSI) Pharmaceuticals

Roche

   Shire Pharma

Takeda

Teva Pharma

   Abingworth Mgmt

EUSA Pharma

Atlas Venture

   Albion Ventures

Andy Richards

Avlar BioVentures

   BSI SA

Advent Venture Partners

Canaccord Adams

   Excalibur Group

ETV Capital

Esperante Ventures

   Edmond de Rothschld Invest

Forbion Capital Partners

H2O Venture Partners

   Genzyme Ventures

H2O Venture Partners

Mercia Tech. Seed Fund

   MPHVM

MVM Life Science

Nomura Code Securities

   Novo A/S

Oxford Capital Partners

Orion Healthcare Equity

   Oxford Tech. Management

Rainbow Seed Fund

Piper Jaffray

   Rosetta Capital

SPARK Ventures

SR One

   Takeda Research Investment

The Wellcome Trust

AbD Serotec

   AdaptImmune

Alchemy Healthcare

Allergan

   Almac Sciences

Apitope

Apex Healthcare Consulting

   Aptuit

AS-Tec Chemicals

ATP Bio

   Avecia Biologics

BASi

BBSRC

   Bench International

BigDNA

BioCentrum (Poland)

   BioCentury

BioConnection B.V.

BioDundee

   Bioedge Pharma

Biomaterials & Tissue Engineering Centre

BioPark

   Biotech Personnel

Biotecnol S.A.

Biotica

   BioUETIKON (Ireland)

Bodium Consulting

Bridgehead International

   CABI

CML Europe

Cancer Research UK

   Canaccord Adams

Caprotec Bioanalytics GmbH

Capsant

   Carbogen Amcis AG

Catalent Pharma Solutions

CellCentric

   Celleron Therapeutics

Cellvax (France)

Cellzome

   Charles Russell LLP

Chroma Therapeutics

Circassia

   CellCentric

CLS Communication

CMP Therapeutics

   CMS Cameron McKenna

Cognitive Drug Research

Comm. Strat. Group, Inc

   Covance Laboratories

CureVac (Germany)

Cytox Group

   D2M

D Young & Co.

De Facto Communications

   Debiopharm SA (Switz)

Domainex

Drug Discovery Today (media)

   Drug Intelligence

EAPD Innovations

EBD Group, Inc.

   Eczacibasi Pharma (Turkey)

Epistem

e-Therapeutics plc

   ETV Capital

Eviva Pharma

Evotec

   Eykona Technologies

FOCUS Insurance

FP7

   Frank B Dehn

Fry Heath Spence

Fulcrum Pharma

   Fusion IP plc

Genzyme

Genzyme Ventures (US)

   George James ltd

Giles Insurance Brokers

Glide Pharma

   GlycoForm

Glysure

Haemostatix

   Health Protection Agency

Heptares

High Commission of Canada

   Hybrid Systems

Immune Targeting Systems

Immunocore

   IMS Health (media)

Inhibox

Inst. Pharma Innovation

   Interea International

International LabMate

Intertek

   Isaac & Co

Ithaka Life Sciences

J A Kemp & Co

   James Cowper

KWS BioTest

Lab Support UK Ltd

   Life Scientific (Ireland)

Manches LLP

MEPC Milton Park

   Mewburn Ellis LLP

Mitsui & Co Europe

MorphoSys UK

   MRC Harwell

Morrison & Foerster

M-Scan

   NDA Analytics

Netherlands FIA

Niche Science & Technology

   Nightingale Associates

Novasep Synthesis

Novolytics

   O2H

OBN

OctoPlus N.V. (Netherlands)

   OI Sciences

Orthox

Oxford BioMedica

   Oxford Expression Tech.

Oxford Gene Technology

Oxford Science Park

   Oxford Transplant Centre

Oxitec

Particle Therapeutics

   Penn Pharma

Pharmaceutical Profiles

PharmaFor

   PharmaLinks

PharmaTV

PharmaProjects

   PharmaVentures

Pharmidex

Pharminox

   Physiomics plc

Pinnacle Associates

PiR Interims

   Plant Vaccines Limited

Polytherics

ProPharma Partners

   Protherics, A BTG Company

PULSE Scientific

Reed Scientific

   RegenTec

Regulatory Resources Group

Riverbank IT Management

   RSSL Pharma

RUSSLAN Clinical Research

Ruston Poole International

   Saint Malo Agglomeration

Saltigo

SCRIP

   SEHTA

Selcia

Simbec Research

   Solace Pharma

Sochinaz / Bachem

Solvias AG (Switzerland)

   SP Industries

Steve D Young & Co

Summit plc

   SynCo Bio Partners B.V.

Syntagon (Sweden)

Syntaxin

   Synth-Isis

Talentmark

Technomark Life Sciences

   Tepnel

Thermal Transfer

Therabel Europe (Ireland)

   ThermoFisher Scientific

Thiakis (now part of Wyeth)

TNO Quality of Life

   TVLSN

Ubichem Plc

UK Trade and Investment

   UniTech Pharma (Sweden)

Université Libre de Bruxelles

Univ. Manc. Incubtor Co.

   Univ. of Manchester IP

VirdisPharma

Wragge & Co LLP

See who else is attending...

...........................................................................................

What other people think:

"My first time at a UK partnering conference was BioTrinity 2008, and I did a deal with an NZ pharma as a direct result". Allen Hakimi, Managing Director at Technomark Life Sciences

"As a direct result of our focused partnering meetings we introduced proteros to potential clients at BioTrinity 2008 which we are pleased to report resulted in several new opportunities and one of which has developed into a substantial business relationship". Gordon J Woodrow, VP at Proteros biostructures GmbH

"...I would like to congratulate you on an excellent meeting.."
Tim Haines, Partner, Abingworth Management

"...Congratulations on such a good event. I had a very productive day with lots of organized and impromptu meetings - a very worthwhile event for me." Dr Charles Potter, CEO, Glide Pharma

Read more testimonials...

Register online now! www.biotrinity.com

Register online now at www.biotrinity.com

............................................................................................

Thanks to our Sponsors:

............................................................................................

BioTrinity is organised by OBN - Rapidly becoming the UK's leading biotech network

OBN 

 

© 2006-2009 OBN

<< Previous: BioTrinity - Keep me informed $32bn Under Management - Meet Life Science VCs at BioTrinity 2009

| Archive Index |

Next: BioTrinity - Keep me informed: Do you know which 35 investors are partnering at BioTrinity 2009? >>

(archive rss , atom )

this list's archives:


This list is for those who wish to stay informed about developments in the BioTrinity conference programme, to find out when there are new announcements, when the online partnering service and company profiles are online, presentation or sponsorship opportunities, and most importantly when registration opens!

BioTrinity - BioPartnering Meeting and Company Showcase
April 2nd-3rd 2009 - Oxford

Subscribe/Unsubscribe on BioTrinity - Keep me informed

* Required



Powered by Dada Mail 3.0.0 beta 3 - 05/19/08
Copyright © 1999-2008, Simoni Creative.

Go back to Visit the BioTrinity website